Tzield™ (teplizumab-mzwv) approved by fda as the first and only treatment indicated to delay the onset of stage 3 type 1 diabetes (t1d) in adult and pediatric patients aged 8 years and older with stage 2 t1d

Tzield is the first disease-modifying therapy in t1d, a life-threatening autoimmune disease in a clinical trial, in stage 2 t1d patients, tzield delayed the median onset of stage 3 t1d by 25 months, or approximately 2 years, compared to placebo stage 3 t1d is associated with significant health risks, including diabetic ketoacidosis, which can be life threatening patients who progress to stage 3 t1d eventually require insulin injections for life investor conference call at 8:00am et tomorrow red bank, n.j. , nov. 17, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the united states food and drug administration (fda) approved the biologics license application (bla) for tzield (teplizumab-mzwv), an anti-cd3-directed antibody, for intravenous use, as the first and only immunomodulatory treatment to delay the onset of stage 3 t1d in adult and pediatric patients aged 8 years and older with stage 2 t1d.
PRVB Ratings Summary
PRVB Quant Ranking